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European jurisprudence give citizens of European Union (EU)
member states the right to seek medical treatment within the
Single Market. In 2004, Germany sanctioned the reimbursement
of medical bills of German patients who seek out-patient care
within the EU by sickness funds even without their prior autho-
rization. OBJECTIVES: To evaluate the impact of choice of
provider abroad on the German health care system as provided
for under the Statutory Health Insurance Modernization Act 
in the context of the sustainability in ﬁnancing health care.
METHODS: Policy analysis of the legislation was carried out
and semi-structured interviews of key stakeholders in the
German health care system, including federal associations of
sickness funds, experts from academia, patient groups and
providers were conducted. CONCLUSIONS: The easing of
access to foreign providers engenders greater satisfaction among
patients and has the potential to improve quality of care at home
via competition among providers at the source country. Given
the crucial safeguards attached to seeking care abroad as in the
case in Germany, the exercise of choice of foreign provider need
not be harmful to the sustainability of the ﬁnancing of the health
care system.
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OBJECTIVES: There is very limited existing research on
national-level racial/ethnic disparities in overall prescription
drug utilization and out-of-pocket prescription drug (OOP PD)
expenditures in working-age adults. This analysis used the 2002
Medical Expenditure Panel Survey (MEPS) to study pharmaceu-
tical use and OOP PD expenditure differences across racial/
ethnic groups, in a nationally representative population of Asian,
Black, Hispanic and White adults age 18–64. METHODS: The
predisposing, enabling, and need framework of the Andersen
Behavioral Model of Health Services Utilization was used to
guide hypotheses and variable selection. MEPS is a national
survey of health care use, expenditures, sources of payment, and
insurance coverage. A negative binomial regression model was
used to analyze the number of annual prescriptions and a two-
part model was used to model annual OOP PD expenditures.
These models adjusted for various demographic, health status,
income and insurance coverage variables. RESULTS: In unad-
justed analyses, Whites ﬁlled an average of 10.1 medicines in
2002; this was signiﬁcantly greater than drug use for Hispanics
(4.72), Blacks (8.55) and Asians (4.1), p-value <0.05 for all com-
parisons. After adjusting for predisposing, enabling and need
factors, statistically signiﬁcant differences in levels of medication
use across racial/ethnic groups remained: compared to Whites,
Asians used 47.8%, Blacks 26.2% and Hispanics 39.1%, fewer
prescription drugs per year. In unadjusted analyses, Whites had
OOP costs of $218, compared to $110, $163, and $75 for His-
panics, Blacks, and Asians, respectively. After adjustment, among
subjects with any drug expenditures, these racial/ethnic groups
had 38%, 30% and 56% lower expenditures compared to
Whites, respectively. CONCLUSIONS: This study found signif-
icant disparities in pharmaceutical use and OOP expenditures
across racial/ethnic groups, even after controlling factors such as
income, insurance coverage and health status. Additional
research is necessary to understand the underlying reasons for
these disparities in use and their impact on patients’ health.
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OBJECTIVE: Therapies for rare diseases are deﬁned as “Orphan
Drugs” (ODs). EMEA appoints this status to products at any
development stage and scientiﬁcally supports companies in the
Marketing Authorisation (MA) process. Funding is regulated by
country-speciﬁc legislation. Scope of this study was to describe
the Italian ODs regulation: deﬁnition, number of authorized
drugs, P&R, time span from designation to European and Italian
MA; national funding criteria. METHODS: EMEA-ODs were
identiﬁed through the ofﬁcial list; authorisation in Italy was
retrieved in the Italian Gazzetta Ufﬁciale. RESULTS: Italian def-
inition of OD reﬂects European legislation. National rules to
identify a cost-effectiveness level for reimbursement are not
established. Among 303 ODs by EMEA (1998–2006), 6% are
authorised in Italy and 94% are not. 11 out of 18 authorized
(61%) (Algasidase-beta, Algasidase-alpha, Arsenic-Trioxide,
Laronidase, Bosentan, Imatinib, Mitotane, Miglutat, Pegviso-
mant, Iloprost, N-carbamyl-L-glutamic-acid) achieved MA
through the P&R negotiation process. The remaining 7 (39%)
are included in “Law-648” list of drugs, for treatment of dis-
eases with “no alternative therapeutic path” and fully NHS-
reimbursed through a dedicated budget. Generally, Italian MA
is obtained 2–4 years after designation and European MA;
Contributed Poster Presentations
Volume 9 • Number 6 • 2006
V A L U E  I N  H E A L T H
A208 © 2006, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/06/A208 A208–A393
